Holen Sie sich die Stockscreener-App
49.38
0.52%
-0.26
Handel nachbörslich:
49.38
Schlusskurs vom Vortag:
$49.64
Offen:
$49.64
24-Stunden-Volumen:
1.94M
Relative Volume:
0.57
Marktkapitalisierung:
$21.94B
Einnahmen:
$2.38B
Nettoeinkommen (Verlust:
$1.32B
KGV:
27.73
EPS:
1.7806
Netto-Cashflow:
$897.24M
1W Leistung:
-1.24%
1M Leistung:
+8.36%
6M Leistung:
+32.53%
1J Leistung:
+54.17%
1-Tages-Spanne:
$49.20
$49.91
1-Wochen-Bereich:
$48.88
$50.08
52-Wochen-Spanne:
$31.84
$50.08
Royalty Pharma Plc Stock (RPRX) Company Profile
Firmenname
Royalty Pharma Plc
Sektor
Branche
Telefon
(212) 883-0200
Adresse
110 EAST 59TH STREET, NEW YORK, NY
Compare RPRX vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RPRX
Royalty Pharma Plc
|
49.38 | 21.94B | 2.38B | 1.32B | 897.24M | 1.7806 |
VRTX
Vertex Pharmaceuticals Inc
|
430.29 | 109.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
751.57 | 79.46B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
780.25 | 48.52B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
305.54 | 40.77B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
300.80 | 33.39B | 5.36B | 287.73M | 924.18M | 2.5229 |
Royalty Pharma Plc Stock (RPRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-30 | Hochstufung | UBS | Neutral → Buy |
| 2025-09-30 | Eingeleitet | Goldman | Buy |
| 2025-05-16 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-06-03 | Herabstufung | UBS | Buy → Neutral |
| 2022-06-14 | Fortgesetzt | UBS | Buy |
| 2022-05-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2022-04-27 | Eingeleitet | Goldman | Buy |
| 2022-04-14 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Overweight |
| 2021-10-29 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-07-30 | Eingeleitet | Tigress Financial | Buy |
| 2020-11-09 | Hochstufung | UBS | Neutral → Buy |
| 2020-07-14 | Eingeleitet | Evercore ISI | In-line |
| 2020-07-13 | Eingeleitet | BofA Securities | Buy |
| 2020-07-13 | Eingeleitet | Citigroup | Neutral |
| 2020-07-13 | Eingeleitet | Cowen | Outperform |
| 2020-07-13 | Eingeleitet | Goldman | Neutral |
| 2020-07-13 | Eingeleitet | JP Morgan | Neutral |
| 2020-07-13 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2020-07-13 | Eingeleitet | SunTrust | Buy |
| 2020-07-13 | Eingeleitet | UBS | Neutral |
Alle ansehen
Royalty Pharma Plc Aktie (RPRX) Neueste Nachrichten
Royalty Pharma declares $0.235 dividend - MSN
Royalty Pharma signs $500M co-development agreement with J&J - MSN
Zurcher Kantonalbank Zurich Cantonalbank Acquires 219,479 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma PLC $RPRX Shares Purchased by Torray Investment Partners LLC - MarketBeat
Precision Trading with Royalty Pharma Plc (RPRX) Risk Zones - Stock Traders Daily
3 Unpopular Stocks We’re Skeptical Of - Yahoo Finance
Ruffer LLP Has $3.50 Million Stake in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma shares edge higher on acquisition of oncology drug royalties - MSN
Royalty Pharma Launches Global Translational Prize to Recognize Breakthrough Scientific Innovation - The Manila Times
A new $1 million prize will honor scientists who turn discoveries into drugs - Stock Titan
Royalty Pharma PLC (NASDAQ:RPRX) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
UBS raises Royalty Pharma stock price target on biopharma catalysts By Investing.com - Investing.com UK
Royalty Pharma (RPRX) PT Raised to $57 at UBS - StreetInsider
Royalty Pharma Approves Dividend and Expands J&J Research Funding - HarianBasis.co
Is It Too Late To Consider Royalty Pharma (RPRX) After Strong 57% One Year Rally? - Sahm
Royalty Pharma Plc Hits New 52-Week High of USD 50.00 - Markets Mojo
Royalty Pharma Plc (RPRX): Investor Outlook With A Promising 3.56% Potential Upside - DirectorsTalk Interviews
Why Royalty Pharma Plc (RPRX) is One of the Most Undervalued Biotech Stocks to Buy Right Now - Yahoo Finance
Moran Wealth Management LLC Grows Position in Royalty Pharma PLC $RPRX - MarketBeat
KBC Group NV Trims Holdings in Royalty Pharma PLC $RPRX - MarketBeat
5 Most Undervalued Biotech Stocks to Buy Right Now - Insider Monkey
Royalty Pharma stock hits 52-week high at $49.07 By Investing.com - Investing.com India
Royalty Pharma declares $0.235 quarterly dividend By Investing.com - Investing.com India
Royalty Pharma PLC (NASDAQ:RPRX) Declares $0.24 Quarterly Dividend - MarketBeat
Royalty Pharma (NASDAQ:RPRX) Hits New 1-Year HighShould You Buy? - MarketBeat
Royalty Pharma stock hits 52-week high at $49.07 - Investing.com
Royalty Pharma plc Declares Dividend for the Second Quarter 2026, Payable on June 10, 2026 - marketscreener.com
Royalty Pharma declares $0.235 quarterly dividend - Investing.com
Royalty Pharma Keeps Quarterly Dividend at $0.235 per Share, Payable June 10 to Shareholders of Record as of May 15 - marketscreener.com
Royalty Pharma Declares Second Quarter 2026 Dividend - The Manila Times
Royalty Pharma plc (RPRX) Declares $0.235 Quarterly Dividend; 1.9% Yield - StreetInsider
Royalty Pharma will pay shareholders 23.5 cents a share on June 10 - Stock Titan
Sumitomo Mitsui Trust Group Inc. Acquires 166,403 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma to Announce Q1 2026 Results on May 6 - National Today
TD Cowen lifts PT on Royalty Pharma plc (RPRX) to $50 from $45, here’s why - MSN
Royalty Pharma : Q1 2026 Pre-Quarterly Results Communication - marketscreener.com
Royalty Pharma to Announce First Quarter 2026 Financial Results on May 6, 2026 - The Manila Times
Royalty Pharma schedules May 6 results, 8 a.m. investor webcast - Stock Titan
Foster Victor Wealth Advisors LLC Takes Position in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma : 2025 Corporate Responsibility Report pdf - marketscreener.com
Can Royalty Pharma (RPRX) Keep the Earnings Surprise Streak Alive? - Yahoo Finance
Robeco Institutional Asset Management B.V. Decreases Holdings in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma plc 8-K Filing – April 2026 Company Information and SEC Disclosure - Minichart
Royalty Pharma funds additional $250M after Phase 3 win for daraxonrasib in metastatic PDAC - TradingView
Royalty Pharma (NASDAQ: RPRX) deepens $2B daraxonrasib royalty and loan pact - Stock Titan
Finanzdaten der Royalty Pharma Plc-Aktie (RPRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
4.01%
0.61%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):